Sign In
Buy MLTX
$18.27
+0.400 (+2.24%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
New York, New York--(Newsfile Corp. - November 23, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) bet
MLTX INVESTOR REMINDER: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit
08:02am, Sunday, 23'rd Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their Options If you purchased or acquire
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
01:23pm, Saturday, 22'nd Nov 2025
NEW YORK , Nov. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10,
MLTX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit
07:44am, Saturday, 22'nd Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their Options If you purchased or acquire
New York, New York--(Newsfile Corp. - November 22, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
03:30pm, Friday, 21'st Nov 2025
LOS ANGELES , Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX)
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its
New York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) bet
New York, New York--(Newsfile Corp. - November 21, 2025) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized law firm,
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
10:12am, Friday, 21'st Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquire
NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLAS
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
